Ovid Therapeutics OVID
Ovid Therapeutics reported $0 revenue and $20.78 million net loss
Ovid Therapeutics (OVID) filed a 10-Q with the SEC on Nov 10, 2026, 7:06 am ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001628280-26-072495
- Revenue: $0 for the three months ended Sep 30, 2026
- Net loss: $20.78 million for the three months ended Sep 30, 2026
- Cash and equivalents: $13.81 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
2 new risk factors · 2 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $0 | $733K | −100% |
| Operating income and margin | −$22.36M | −$15.7M | −43% |
| Net income | −$20.78M | −$15.01M | −39% |
| Operating cash flow | −$15.88M | −$17.59M | +9.8% |
| Cash | $13.81M | $11.33M | +22% |
New risk factors (2)
- A key element of our current strategy is to discover, develop and potentially commercialize a portfolio of drug candidates to treat certain brain disorders with significant unmet need. However, our business development activities and research activities may present attractive opportunities outside of our current…
- Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence control over matters subject to stockholder approval. +1 more paragraph
Removed risk factors (2)
- It may be difficult and/or costly to detect, investigate, mitigate, contain and remediate a security incident. Our efforts to do so may not be successful. Actions taken by us or the third parties with whom we work to detect, investigate, mitigate, contain and remediate a security incident could result in outages…
- Concentration of ownership of our common stock among our executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions. +1 more paragraph